Abbott Laboratories


  • MUMBAI, July 14- India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..

  • Will earnings tell the story markets need to hear? Sunday, 13 Jul 2014 | 6:21 PM ET
    Traders work the floor of the New York Stock Exchange before the closing bell in New York.

    Quarterly earnings growth and clues from companies' commentaries will tell whether there really will be a bounce back in growth in the second half.

  • Mylan nears major deal for Abbott drugs: Sources Friday, 11 Jul 2014 | 6:42 PM ET

    U.S. generic drugmaker Mylan is said to be in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott Laboratories.

  • AbbVie raises its bid for Shire by about 11 pct Tuesday, 8 Jul 2014 | 8:53 AM ET

    NEW YORK— U.S. drugmaker AbbVie has boosted its offer for Shire by 11 percent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart. North Chicago, Illinois- based AbbVie is now making an unsolicited offer of 51.15 British pounds per Shire PLC share in cash and stock.

  • "I'm grateful that the SEC took the time to consider all the facts and drop the investigation," Matthew Korenberg, the former Goldman banker, said. Korenberg's lawyer John Hueston said the SEC had initially authorized its staff to take action against Korenberg, 39, who worked in San Francisco on Goldman's healthcare team.

  • *Says deal would boost new AbbVie's adjusted EPS materially. LONDON, June 25- U.S. drugmaker AbbVie said on Wednesday it wanted to move rapidly to clinch a takeover of Shire as it set out the strategic rationale for buying the London- listed company, which has spurned its $46 billion offer.

  • NEW YORK, June 24- U.S. stock index futures pointed to a flat open on Tuesday, suggesting investors continued to search for direction following a sharp rally that took indexes to records last week.

  • US STOCKS-Futures edge lower, consumer data awaited Tuesday, 24 Jun 2014 | 7:17 AM ET

    NEW YORK, June 24- U.S. stock index futures fell on Tuesday, suggesting investors continued to search for direction following a sharp rally that took indexes to records last week. *Equities had a quiet session on Monday, with trading volume light and moves so slight the S&P 500 had one of its narrowest intraday trading ranges ever, according to MKM Partners.

  • MOSCOW, June 24- U.S. healthcare firm Abbott Laboratories is to buy Russian drugmaker Veropharm for up to $495 million, giving it a manufacturing presence in a country where it has been operating for nearly 40 years, Abbott said on Tuesday.

  • MUMBAI, June 24- The government of India is likely to raise the number of drugs deemed essential and subject to price caps, people directly involved in the process said.

  • June 23- U.S. drugmaker AbbVie Inc, which is trying to buy London- listed peer Shire, on Monday raised its 2014 adjusted earnings forecast, citing strong "business performance" that it expects to continue for the rest of the year.

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • June 16- Medtronic Inc's $43 billion deal for Dublin- based Covidien Plc should accelerate already intense efforts by medical device rivals to seek merger partners, industry analysts and bankers said on Monday.

  • Medtronic’s $43B Covidien deal: More to come? Monday, 16 Jun 2014 | 9:26 AM ET
    Medtronic Chairman and Chief Executive Omar Ishrak.

    Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.

  • Early movers: BEAV, KORS, S, FB, SNE, TWX & more Tuesday, 10 Jun 2014 | 7:49 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Infant formula makers must test for germs, nutrients Tuesday, 10 Jun 2014 | 7:36 AM ET

    U.S. health officials finalized guidelines for infant formula makers that aim to ensure products meet certain quality controls to keep them safe.

  • Mead Johnson Nutrition Co in 2011 saw its shares fall when stores pulled some powdered versions of its Enfamil product over concerns about infection, although the FDA later said a recall was not needed. The new rule, the FDA said, is aimed at establishing "good manufacturing practices" that many companies have already adopted voluntarily.

  • Obesity game-changer? Why this time it's different Monday, 9 Jun 2014 | 12:45 PM ET

    An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.

  • LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. Private equity firms approached by GSK include Advent International, Blackstone and KKR, the sources said, and the drugmaker is being advised by Lazard.

  • Midday movers: AT&T, DirecTV, AstraZeneca & more Monday, 19 May 2014 | 12:15 PM ET

    Take a look at some of Monday's midday movers: